文献速递神经免疫

多发性硬化首次脱髓鞘事件未接受高效药物治疗患者血清神经丝轻链水平与残疾恶化的关联

Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项多中心队列研究纳入578例首次脱髓鞘事件提示多发性硬化的患者,在发病12个月内检测血清神经丝轻链(sNfL),评估其与6个月确认的残疾恶化(CDW)及EDSS评分3分的关联。结果显示sNfL>10 pg/mL与两个队列中6个月CDW和EDSS 3分风险升高独立相关,高效疾病修正治疗与高sNfL患者较低风险相关。

要点

  • sNfL>10 pg/mL与6个月CDW风险升高独立相关(开发队列HR 2.39,验证队列HR 1.61)。
  • sNfL>10 pg/mL与EDSS 3分风险升高独立相关(开发队列HR 4.12,验证队列HR 2.03)。
  • 高基线sNfL患者中,高效疾病修正治疗与6个月CDW和EDSS 3分风险降低相关。

核心结论

  • 发病第一年内的高sNfL值与多发性硬化长期残疾恶化相关,提示检测sNfL水平可能有助于识别高效疾病修正治疗的最佳候选者。

研究设计与样本

  • 多中心队列研究,纳入578例首次脱髓鞘事件提示多发性硬化的患者,开发队列327例来自Hospital Universitario Ramón y Cajal(1994年6月1日至2021年9月31日,随访至2022年8月31日),验证队列251例来自8家西班牙医院(1995年10月1日至2020年8月4日,随访至2022年8月16日)。
  • 临床评估至少每6个月一次。
  • sNfL在发病后12个月内采集的血样中使用单分子阵列试剂盒检测,截断值为10 pg/mL和标准化评分(z评分)1.5。
  • 采用多变量Cox比例风险回归模型评估结局。

主要发现

  • 开发队列中,sNfL>10 pg/mL与6个月CDW风险升高独立相关(HR 2.39;95%CI 1.39-4.12;P=.002),与EDSS 3分风险升高独立相关(HR 4.12;95%CI 2.18-7.77;P<.001)。
  • 验证队列中,sNfL>10 pg/mL与6个月CDW风险升高独立相关(HR 1.61;95%CI 1.07-2.42;P=.02),与EDSS 3分风险升高独立相关(HR 2.03;95%CI 1.23-3.33;P=.005)。
  • 高基线sNfL值患者中,高效疾病修正治疗与6个月CDW和EDSS 3分风险降低相关。

关键数值与推荐

  • sNfL截断值:10 pg/mL和标准化评分(z评分)1.5。
  • 主要结局:6个月确认的残疾恶化(CDW)和EDSS评分3分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The value of serum neurofilament light chain (sNfL) levels for predicting long-term disability in patients with multiple sclerosis (MS) remains controversial. OBJECTIVE: To assess whether high sNfL values are associated with disability worsening in patients who underwent their first demyelinating MS event. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study included patients who underwent their first demyelinating event suggestive of MS at Hospital Universitario Ramón y Cajal (development cohort; June 1, 1994, to September 31, 2021, with follow-up until August 31, 2022) and 8 Spanish hospitals (validation cohort; October 1, 1995, to August 4, 2020, with follow-up until August 16, 2022). EXPOSURES: Clinical evaluations at least every 6 months. MAIN OUTCOMES AND MEASURES: The main outcomes were 6-month confirmed disability worsening (CDW) and an Expanded Disability Status Scale (EDSS) score of 3. Levels of sNfL were measured in blood samples obtained within 12 months after disease onset using a single molecule array kit. The cutoffs used were sNfL level of 10 pg/mL and a standardized score (z score) of 1.5. Multivariable Cox proportional hazards regression models were used to evaluate outcomes. RESULTS: Of the 578 patients included in the study, 327 were in the development cohort (median age at sNfL analysis, 34.1 years [IQR, 27.2-42.7 years]; 226 female [69.1%]) and 251 patients were in the validation cohort (median age at sNfL analysis, 33.3 years [IQR, 27.4-41.5 years]; 184 female [73.3%]). The median follow-up was 7.10 years (IQR, 4.18-10.0 years). Levels of sNfL greater than 10 pg/mL were independently associated with higher risk of 6-month CDW and an EDSS of 3 in the development cohort (6-month CDW: hazard ratio [HR], 2.39; 95% CI, 1.39-4.12; P = .002; EDSS of 3: HR, 4.12; 95% CI, 2.18-7.77; P < .001) and the validation cohort (6-month CDW: HR, 1.61; 95% CI, 1.07-2.42; P = .02; EDSS of 3: HR, 2.03; 95% CI, 1.23-3.33; P = .005). Highly effective disease-modifying treatments were associated with lower risks of 6-month CDW and an EDSS of 3 in patients with high baseline sNfL values. CONCLUSIONS AND RELEVANCE: This cohort study found that high sNfL values obtained within the first year of disease were associated with long-term disability worsening in MS, suggesting that sNfL level measurement may help identify optimal candidates for highly effective disease-modifying treatments.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Monreal E, Fernández-Velasco JI, García-Sánchez MI, et al. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs. JAMA Neurol. 2023. PMID: 36848127. doi:10.1001/jamaneurol.2023.0010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。